Study: NCT00182793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Cycle 1: 6 mg/kg on day -2 from PBSC reinfusion Cycle 2: 6 mg/kg on day -7 from PBSC reinfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Description: Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Description: Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Description: Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support
Description: Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.~Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy.